Company news

Proteomics International Laboratories Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

A landmark in non-invasive Esophageal Cancer diagnosis

June 4, 2025

$12 million capital raise completed with oversubscribed SPP

June 4, 2025

PromarkerEndo latest results presented at world congress

May 25, 2025

Chinese patent granted for OxiDx technology

May 14, 2025

Share Purchase Plan Offer Booklet

May 5, 2025

$4.5m placement to launch Promarker diagnostics

April 22, 2025

Trading Halt

April 16, 2025

Pause in Trading

April 16, 2025

Australian patent granted for OxiDx oxidative stress test

March 27, 2025

Response to ASX Aware Query

March 16, 2025

PromarkerD predictive test for DKD launched in Australia

March 12, 2025

PromarkerD outperforms conventional tests--results published

March 10, 2025

Proteomics opens CLIA certified reference laboratory in USA

February 27, 2025

Interim Financial Report and Appendix 4D

February 25, 2025

December 2024 Quarterly Activities Report and Appendix 4C

January 20, 2025

Novel OxiDx test detects muscle damage in elite athletes

December 30, 2024

Breakthrough results for endometriosis diagnostic blood test

December 29, 2024

Proteomics receives $2.16 million in R&D tax incentive

December 15, 2024

AGM Chairman's Address and Investor Presentation

November 8, 2024

September 2024 Quarterly Activities Report and Appendix 4C

October 21, 2024

Esophageal cancer diagnostic delivers excellent results

September 22, 2024

Update on commercialisation of PromarkerD in the USA

September 10, 2024

Groundbreaking results for type 1 diabetes and kidney health

August 22, 2024

June 2024 Quarterly Activities Report and Appendix 4C

July 29, 2024

Eurobio Scientific to sell PromarkerD DKD test in France

June 23, 2024

Proteomics appoints medical devices sales agency for Europe

June 16, 2024

March 2024 Quarterly Activities Report and Appendix 4C

April 16, 2024

Proteomics signs with Oxford Univ to validate test for Endo

March 24, 2024

PromarkerD US commercialisation & Promarker pipeline update

March 17, 2024

European patent granted for OxiDx technology

February 27, 2024

Study validates biomarkers for oesophageal cancer blood test

January 31, 2024

Study validates biomarkers for endometriosis blood test

January 31, 2024

Proteomics to raise $6.5m through Institutional Placement

January 22, 2024

December 2023 Quarterly Activities Report and Appendix 4C

January 22, 2024

PromarkerD licence with Omics Global extended to Chile

December 19, 2023

US Medicare confirms reimbursement price for PromarkerD

November 21, 2023

Proteomics receives $1.85 million in R&D tax incentive

November 8, 2023

September 2023 Quarterly Activities Report and Appendix 4C

October 25, 2023

Reinstatement to Quotation

September 28, 2023

PromarkerD US reimbursement price & Aus regulatory decision

September 28, 2023

Suspension from Quotation

September 18, 2023

New oesophageal cancer test presented at global conference

September 7, 2023

OxiDx platform technology secures patent in Japan

September 3, 2023

June 2023 Quarterly Activities Report and Appendix 4C

July 23, 2023

Sonic Healthcare USA signs licence for PromarkerD in the US

May 10, 2023

World Endometriosis Congress - New diagnostic test showcased

May 4, 2023

Canagliflozin lowers PromarkerD DKD risk prediction scores

May 2, 2023

March 2023 Quarterly Activities Report and Appendix 4C

April 26, 2023

Proteomics renews ISO 13485 and ISO 17025 accreditations

April 16, 2023

New endometriosis test presented at international conference

March 24, 2023

← Newer news releases · Older news releases →

Decks

The 5 newest of 46 decks. Every deck is listed under its year.